Patents by Inventor Alan F. Wahl

Alan F. Wahl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100129362
    Abstract: Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunomodulatory without conjugation to a therapeutic agents as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment of psoriatic arthritis comprising administering the CD70 binding agents to a subject.
    Type: Application
    Filed: November 16, 2009
    Publication date: May 27, 2010
    Applicant: SEATTLE GENETICS, INC.
    Inventors: CHE-LEUNG LAW, JULIE MCEARCHERN, ALAN F. WAHL
  • Patent number: 7666422
    Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.
    Type: Grant
    Filed: January 20, 2009
    Date of Patent: February 23, 2010
    Assignee: Seattle Genetics, Inc.
    Inventors: Clay B. Siegall, Alan F. Wahl, Joseph A. Francisco, Henry Perry Fell, Jr.
  • Patent number: 7662387
    Abstract: Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic, immunosuppressive, or other therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the disclosed pharmaceutical compositions.
    Type: Grant
    Filed: February 20, 2004
    Date of Patent: February 16, 2010
    Assignee: Seattle Genetics
    Inventors: Che-Leung Law, Alan F. Wahl, Nathalie Scholler, Linda A. Pestano
  • Patent number: 7641903
    Abstract: Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunomodulatory without conjugation to a therapeutic agents as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological disorders comprising administering the CD70 binding agents to a subject.
    Type: Grant
    Filed: April 13, 2007
    Date of Patent: January 5, 2010
    Assignee: Seattle Genetics, Inc.
    Inventors: Che-Leung Law, Julie McEarchern, Alan F. Wahl
  • Publication number: 20090304590
    Abstract: The present application provides novel binding proteins, including human binding proteins that specifically bind to the human ErbB2.
    Type: Application
    Filed: October 27, 2008
    Publication date: December 10, 2009
    Applicants: Wyeth, Trubion Pharmaceuticals, Inc.
    Inventors: Davinder Singh Gill, Laird Bloom, Maximillian T. Follettie, Fionnuala McAleese, Sreekumar Kodangattil, John Francis DiJoseph, Nitin K. Damle, Peter R. Baum, Peter A. Thompson, John C. Kumer, Alan F. Wahl, Paul A. Algate, Sateesh Kumar Natarajan
  • Publication number: 20090280117
    Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.
    Type: Application
    Filed: January 20, 2009
    Publication date: November 12, 2009
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Clay B. Siegall, Alan F. Wahl, Joseph A. Francisco, Henry Perry Fell, JR.
  • Publication number: 20090232806
    Abstract: Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunomodulatory without conjugation to a therapeutic agents as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological disorders comprising administering the CD70 binding agents to a subject.
    Type: Application
    Filed: February 12, 2009
    Publication date: September 17, 2009
    Applicant: Seattle Genetics, Inc.
    Inventors: Che-Leung Law, Julie McEarchern, Alan F. Wahl
  • Patent number: 7510711
    Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.
    Type: Grant
    Filed: April 8, 2005
    Date of Patent: March 31, 2009
    Assignee: Seattle Genetics, Inc.
    Inventors: Clay B. Siegall, Alan F. Wahl, Joseph A. Francisco, Henry Perry Fell, Jr.
  • Publication number: 20090074772
    Abstract: Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunosuppressive without conjugation to a therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological disorders comprising administering to a subject the CD70-binding agent.
    Type: Application
    Filed: November 5, 2008
    Publication date: March 19, 2009
    Applicant: Seattle Genetics, Inc.
    Inventors: Che-Leung Law, Julie McEarchern, Alan F. Wahl
  • Patent number: 7498032
    Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.
    Type: Grant
    Filed: May 14, 2004
    Date of Patent: March 3, 2009
    Assignee: Seattle Genetics, Inc.
    Inventors: Clay B. Siegall, Alan F. Wahl, Joseph A. Francisco, Henry Perry Fell, Jr.
  • Patent number: 7491390
    Abstract: Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunosuppressive without conjugation to a therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological disorders comprising administering to a subject the CD70-binding agent.
    Type: Grant
    Filed: October 14, 2005
    Date of Patent: February 17, 2009
    Assignee: Seattle Genetics, Inc.
    Inventors: Che-Leung Law, Julie McEarchern, Alan F. Wahl
  • Publication number: 20080317747
    Abstract: The present invention relates to methods and compositions for the treatment of Hodgkin's Disease, comprising administering proteins characterized by their ability to bind to CD30, or compete with monoclonal antibodies AC10 or HeFi-1 for binding to CD30, and exert a cytostatic or cytotoxic effect on Hodgkin's disease cells in the absence of effector cells or complement. Such proteins include derivatives of monoclonal antibodies AC10 and HeFi-1. The proteins of the invention can be human, humanized, or chimeric antibodies; further, they can be conjugated to cytotoxic agents such as chemotherapeutic drugs. The invention further relates to nucleic acids encoding the proteins of the invention. The invention yet further relates to a method for identifying an anti-CD30 antibody useful for the treatment or prevention of Hodgkin's Disease.
    Type: Application
    Filed: May 7, 2008
    Publication date: December 25, 2008
    Applicant: Seattle Genetics, Inc.
    Inventors: Joseph A. Francisco, Grant Risdon, Alan F. Wahl, Clay Siegall, Peter D. Senter, Sveltana Doronina, Brian E. Toki
  • Publication number: 20080213289
    Abstract: The present invention relates to methods and compositions for the treatment of Hodgkin's Disease, comprising administering proteins characterized by their ability to bind to CD30, or compete with monoclonal antibodies AC10 or HeFi-1 for binding to CD30, and exert a cytostatic or cytotoxic effect on Hodgkin's disease cells in the absence of effector cells or complement. Such proteins include derivatives of monoclonal antibodies AC10 and HeFi-1. The proteins of the invention can be human, humanized, or chimeric antibodies; further, they can be conjugated to cytotoxic agents such as chemotherapeutic drugs. The invention further relates to nucleic acids encoding the proteins of the invention. The invention yet further relates to a method for identifying an anti-CD30 antibody useful for the treatment or prevention of Hodgkin's Disease.
    Type: Application
    Filed: January 18, 2008
    Publication date: September 4, 2008
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Joseph A. Francisco, Grant Risdon, Alan F. Wahl, Clay Siegall, Peter D. Senter, Svetlana Doronina, Brian E. Toki
  • Publication number: 20080138343
    Abstract: Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunosuppressive without conjugation to a therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological disorders comprising administering to a subject the CD70-binding agent.
    Type: Application
    Filed: January 18, 2008
    Publication date: June 12, 2008
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Che-Leung Law, Julie McEarchern, Alan F. Wahl
  • Publication number: 20080138341
    Abstract: Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunosuppressive without conjugation to a therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological disorders comprising administering to a subject the CD70-binding agent.
    Type: Application
    Filed: January 18, 2008
    Publication date: June 12, 2008
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Che-Leung Law, Julie McEarchern, Alan F. Wahl
  • Patent number: 7090843
    Abstract: The present invention relates to methods and compositions for the treatment of Hodgkin's Disease, comprising administering proteins characterized by their ability to bind to CD30, or compete with monoclonal antibodies AC10 or HeFi-1 for binding to CD30, and exert a cytostatic or cytotoxic effect on Hodgkin's Disease cells. Such proteins include derivatives of monoclonal antibodies AC10 and HeFi-1. The proteins of the invention can be human, humanized, or chimeric antibodies; further, they can be conjugated to cytotoxic agents such as chemotherapeutic drugs. The invention further relates to nucleic acids encoding the proteins of the invention. The invention yet further relates to a method for identifying an anti-CD30 antibody useful for the treatment or prevention of Hodgkin's Disease.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: August 15, 2006
    Assignee: Seattle Genetics, Inc.
    Inventors: Joseph A. Francisco, Grant Risdon, Alan F. Wahl, Clay Siegall
  • Patent number: 6946129
    Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.
    Type: Grant
    Filed: June 8, 1999
    Date of Patent: September 20, 2005
    Assignee: Seattle Genetics, Inc.
    Inventors: Clay B. Siegall, Alan F. Wahl, Joseph A. Francisco, Henry Perry Fell, Jr.
  • Patent number: 6843989
    Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: January 18, 2005
    Assignee: Seattle Genetics, Inc.
    Inventors: Clay B. Siegall, Alan F. Wahl, Joseph A. Francisco, Henry Perry Fell, Jr.
  • Patent number: 6838261
    Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: January 4, 2005
    Assignee: Seattle Genetics, Inc.
    Inventors: Clay B. Siegall, Alan F. Wahl, Joseph A. Francisco, Henry Perry Fell, Jr.
  • Publication number: 20040235074
    Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise, administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.
    Type: Application
    Filed: May 14, 2004
    Publication date: November 25, 2004
    Applicant: Seattle Genetics, Inc.
    Inventors: Clay B. Siegall, Alan F. Wahl, Joseph A. Francisco, Henry Perry Fell